Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
Chiesi Farmaceutici SpA agreed to acquire US-listed KalVista Pharmaceuticals Inc. for about $1.9 billion in its biggest acquisition to date, expanding the Italian company’s rare immunology portfolio.
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.